bit.bio raises in excess of $100 million in first close of Series B financing

Today bit.bio announces the first close of their Series B financing of $103 million.

New and existing institutional and strategic investors in the Series B round, thus far, include Arch Ventures, Charles River Laboratories, Foresite Capital, National Resilience, Inc. (Resilience), Metaplanet, Puhua Capital and Tencent.

The funding will accelerate the clinical development of the company’s proprietary cell coding technology opti-ox - a breakthrough gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently at scale through direct reprogramming of stem cells.

It will also support the continued growth of the company’s ioCells product portfolio - where opti-ox is used to create human cell products that are unique because they offer consistency at scale and the cells are highly defined. Access to ioCells enables our partners and customers to conduct translational research and drug development with physiologically relevant human cell models. Using human cells to bridge the translation gap in drug development will improve chances of clinical success and the potential to unlock a new generation of medicines.

bit.bio has already launched two products for research and drug discovery - glutamatergic neurons and skeletal myocytes - with disease models and other cell types to follow.

I’m thrilled that bit.bio is supported by world class investors and strategic partners. The capital will enable us to accelerate our clinical and commercial scale-up and to deliver cell therapies for every patient, everywhere.”

Mark Kotter, CEO and Founder, bit.bio

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    bit.bio. (2021, November 06). bit.bio raises in excess of $100 million in first close of Series B financing. AZoLifeSciences. Retrieved on May 25, 2024 from https://www.azolifesciences.com/news/20211106/bitbio-raises-in-excess-of-24100-million-in-first-close-of-Series-B-financing.aspx.

  • MLA

    bit.bio. "bit.bio raises in excess of $100 million in first close of Series B financing". AZoLifeSciences. 25 May 2024. <https://www.azolifesciences.com/news/20211106/bitbio-raises-in-excess-of-24100-million-in-first-close-of-Series-B-financing.aspx>.

  • Chicago

    bit.bio. "bit.bio raises in excess of $100 million in first close of Series B financing". AZoLifeSciences. https://www.azolifesciences.com/news/20211106/bitbio-raises-in-excess-of-24100-million-in-first-close-of-Series-B-financing.aspx. (accessed May 25, 2024).

  • Harvard

    bit.bio. 2021. bit.bio raises in excess of $100 million in first close of Series B financing. AZoLifeSciences, viewed 25 May 2024, https://www.azolifesciences.com/news/20211106/bitbio-raises-in-excess-of-24100-million-in-first-close-of-Series-B-financing.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
bit.bio appoints Kathryn Corzo as Chief Operating Officer